Home > Boards > US Listed > Biotechs >

Lineage Cell Therapeutics, Inc. (LCTX)

LCTX RSS Feed
Add LCTX Price Alert      Hide Sticky   Hide Intro
Moderator:
Search This Board: 
Last Post: 11/12/2019 7:27:42 PM - Followers: 71 - Board type: Free - Posts Today: 0

 

BioTime, Inc.  (BTX)

 

 
 

 

http://www.biotimeinc.com/

 

 

 

Company Information:

BioTime, Inc.
1301 Harbor Bay Parkway
Alameda, CA 94502

Phone: 510-521-3390
      Fax: 510-521-3389

 

CIK

0000876343

 

 

BioTime, Inc. (NYSE AMEX: BTX) is a biotechnology company engaged in two areas of biomedical research and product development:

  • Stem cell technology and products for use in regenerative medicine.  These products and technologies are being developed and marketed by our wholly owned subsidiary Embryome Sciences, Inc.
  • Blood plasma volume expanders and related technology for use in surgery, emergency trauma treatment and other applications.  Our lead product is Hextend® which is being marketed by Hospira, Inc. and CJ CheilJedang Corp. under exclusive licenses from us

 

The Potential of Regenerative Medicine

Regenerative medicine refers to therapies based on human embryonic stem ("hES") cell technology that are designed to rebuild cell and tissue function lost due to degenerative disease or injury. The great scientific and public interest in regenerative medicine lies in the potential of hES cells to transform into any cell type of the human body. hES cells therefore show considerable potential as a source of new therapies for a host of currently-incurable diseases such as: diabetes, stroke, Alzheimer's and Parkinson's disease, heart failure, arthritis, muscular dystrophy, spinal cord injury, macular degeneration, hearing loss, kidney and liver failure, as well as many other disorders that may be treated by replacing diseased or damaged organ tissues. In response to the unusual potential of the field, the State of California has allocated $3 billion over the next 10 years to fund basic research, and President Obama has lifted previous restrictions for federal funding of stem cell research.

Led by Dr. Michael West, considered by many to be a founding father of the stem cell industry, BioTime has assembled an array of products and associated intellectual property that give it the potential to be a leader in this exciting new field of medicine.

We are implementing a near-term revenues strategy in the regenerative medicine field by seeking to develop and market advanced hES products and technology that can be used by researchers at universities and biopharmaceutical companies. These research-only products generally can be marketed without regulatory (FDA) approval, and are therefore relatively near-term business opportunities when compared to human therapeutic products. We may also initiate development programs for human therapeutic applications if sufficient capital becomes available to us or through joint efforts with industry partners.

BioTime is leveraging its product development strategy on two key technology platforms:
 

  • • An advanced iPS technology allowing the transformation of human cells of the body back to a primordial stem cell state equivalent to embryonic stem cells. Using this technology with patient specific stem cells, rather than stem cells derived from embryos donated by unrelated people, may reduce the incidence of rejection of tissue grafts.
     
  • ACTCellerate™ technology that permits the generation of scalable and highly purified cells of the human body.

See this link for more information:  http://www.biotimeinc.com/aboutBT.htm

 

 

 

 

 

 

Management: 

http://www.biotimeinc.com/management.htm
 

 

Dr. Michael West, CEO

Dr. West is the Chief Executive Officer of BioTime, Inc. (NYSE AMEX: BTIM) and Embryome Sciences, Inc. of Alameda, California. The Companies are focused on developing an array of research and therapeutic products using human embryonic stem cell technology. He received his Ph.D. from Baylor College of Medicine in 1989 concentrating on the biology of cellular aging. He has focused his academic and business career on the application of developmental biology to the age-related degenerative disease. He was the Founder of Geron Corporation of Menlo Park, California (Nasdaq: GERN) and from 1990 to 1998 he was a Director, and Vice President, where he initiated and managed programs in telomerase diagnostics, oligonucleotide-based telomerase inhibition as anti-tumor therapy, and the cloning and use of telomerase in telomerase-mediated therapy wherein telomerase is utilized to immortalize human cells. From 1995 to 1998 he organized and managed the research collaboration between Geron and its academic collaborators James Thomson and John Gearhart that led to the first isolation of human embryonic stem and human embryonic germ cells. From 1998 to 2007 he was President and Chief Scientific Officer at Advanced Cell Technology, Inc. (OTCBB: ACTC) where he managed programs in animal cloning, human somatic cell nuclear transfer, retinal differentiation, and ACTCellerate, a technology for the multiplex derivation and characterization of clonal human embryonic progenitor cell lines. 

Dr. West's complete CV and background on his research interests are available online at: http://www.michaelwest.org/


 

 

 

 

Recent News: 

http://www.b2i.us/profiles/investor/ResLibrary2.asp?BzID=1152&GoTopage=&Category=1802&t=
 

 

http://finance.yahoo.com/q/h?s=BTX+Headlines

 

Subsidiaries
http://www.biotimeinc.com/subsidiaries/


 

 

Filings:

http://www.sec.gov/cgi-bin/browse-edgar?company=&match=&CIK=0000876343&filenum=&State=&Country=&SIC=&owner=exclude&Find=Find+Companies&action=getcompany

 

 

Transfer Agent:

American Stock Transfer & Trust Company
59 Maiden Lane
New York 10038

 

Investor Relations:

Judith Segall

VP of Administration, Corporate Secretary

isegall@biotimemail.com

Phone:  510.521.3390 ext 301

 

 

 


 

 

All messages, including iBox content, are the opinion of the posters, are no substitute for your own research, and should not be relied upon for stock trading or any other purpose.

Also, keep in mind that moderators may or may not have a position in said stock.   Being a moderator isn't a sign of endorsement.

  

Please keep your posts on topic because your message(s) will probably be deleted when:
* Posting content that's off-topic to the subject of this board;
* Posting statements that don't add value to the discussion; or
* When you violate any other posting term of the iHub User Agreement:
http://investorshub.advfn.com/boards/complex_terms.asp

 

LCTX
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
LCTX News: Lineage Cell Therapeutics Provides Update on SCiStar Clinical Study and OPC1 Spinal Cord Injury Program 11/15/2019 08:00:00 AM
LCTX News: Lineage Cell Therapeutics Reports Third Quarter 2019 Financial Results and Provides Business Update 11/12/2019 04:05:00 PM
LCTX News: Lineage Cell Therapeutics to Host Therapeutic Area Experts at Solebury Trout Investor Event on November 15, 2019 10/28/2019 08:00:00 AM
LCTX News: Lineage Cell Therapeutics Presents Encouraging Data on Vision Restoration Program at Society for Neuroscience’s 49th Annual... 10/23/2019 08:00:00 AM
LCTX News: Lineage Cell Therapeutics to Present at Dawson James Securities 5th Annual Small Cap Growth Conference on October 29, 2019 10/22/2019 08:00:00 AM
PostSubject
#1188   Lineage Cell Therapeutics Reports Third Quarter 2019 Financial abracky 11/12/19 07:27:42 PM
#1187   Lineage Cell Therapeutics to Report Third Quarter 2019 abracky 11/05/19 05:25:23 PM
#1186   Lineage Cell Therapeutics to Host Therapeutic Area Experts abracky 10/28/19 03:38:48 PM
#1185   Lineage Cell Therapeutics Presents New OpRegen® Data at abracky 10/15/19 01:25:39 PM
#1184   OpRegen show's success in Dry AMD and was ahab333 10/15/19 12:06:31 PM
#1183   Lineage Cell Therapeutics to Chair Session & Present abracky 10/07/19 03:38:55 PM
#1182   Lineage Cell Therapeutics to Present New OpRegen® Data abracky 10/02/19 03:28:15 PM
#1181   LCTX is now looking to partner with Revevia ahab333 09/25/19 11:09:26 AM
#1180   Lineage Cell Therapeutics to Present at 2019 Cell abracky 09/24/19 04:41:29 AM
#1179   * * $LCTX Video Chart 09-19-2019 * * ClayTrader 09/19/19 05:15:38 PM
#1178   Here is some good news for LCTX ahab333 09/19/19 09:42:05 AM
#1177   Lineage Cell Therapeutics Conducts Sale of Shares in abracky 09/11/19 03:49:49 PM
#1175   Lineage Cell Therapeutics to Present at H.C. Wainwright abracky 09/05/19 10:03:33 AM
#1174   That's nice to see. The information came from pymadams 09/04/19 02:44:26 PM
#1173   Lineage Cell Therapeutics Announces Data From Vision Restoration abracky 09/03/19 02:17:03 PM
#1172   Someone needs to start a LCTX board. abracky 08/26/19 12:29:07 PM
#1171   Lineage Cell Therapeutics Announces Issuance of U.S. Patent abracky 08/26/19 12:24:13 PM
#1170   The latest presentation on the LCTX website shows pymadams 08/23/19 04:17:35 AM
#1169   Cincy, I am just waiting for the next ahab333 08/21/19 02:42:35 PM
#1168   If we look at last quarterly reports of Cincinnatus 08/21/19 12:35:07 PM
#1167   Current Report Filing (8-k) Source: Edgar (US Regulatory)       UNITED STATES abracky 08/12/19 11:29:56 AM
#1166   Thanks for the update Abracky & GLTU ahab333 08/08/19 11:51:49 AM
#1165   BioTime to Report Second Quarter 2019 Financial Results abracky 08/06/19 03:38:46 PM
#1164   Time to BUY at this range imo. The Cannabisprince 07/04/19 03:18:20 PM
#1163   AGE didn't specify which program(s) they were reducing bobby2loaves 05/20/19 07:47:04 AM
#1162   Thanks, bobby. I hadn't had time to review tradetrak 05/19/19 10:40:33 PM
#1161   OK - I went through the AGE quarterly bobby2loaves 05/18/19 08:09:03 AM
#1160   tradetrak, The 1/4ly wasn't too bad IMO but ahab333 05/17/19 11:59:05 AM
#1159   Anybody know why we're under so much pressure tradetrak 05/14/19 05:29:35 PM
#1158   This report came to my email from IR ahab333 04/26/19 11:56:01 AM
#1157   The big boys are increasing their stake here Cannabisprince 03/20/19 07:39:19 PM
#1156   End of the day though wallstreethustler 03/15/19 05:17:22 PM
#1155   Summary: we are establishing a new corporate Brand DeepDive 03/15/19 12:30:37 AM
#1154   4th Biotime Quarter & full 2018 financial reports --- ahab333 03/14/19 05:51:16 PM
#1153   DD, we will see about cashing burning ways ahab333 03/14/19 10:55:59 AM
#1152   BTX continues on its cash burning ways. DeepDive 03/11/19 11:21:52 AM
#1151   New on the Asterias/Biotime acquistion is now completed ahab333 03/11/19 11:07:35 AM
#1150   I too am waiting to hear if they ahab333 03/07/19 05:39:00 PM
#1149   Thanks, I saw the post. Let's hope Cincinnatus 03/07/19 03:54:05 PM
#1148   Cincinnatus, I just got an email that the ahab333 03/07/19 01:16:03 PM
#1147   BTX on or around March 21 techxen 02/18/19 03:43:16 PM
#1146   Anyone have a date for earnings call for Cincinnatus 02/12/19 01:07:44 PM
#1145   Very few posts reflects the very little material DeepDive 02/03/19 12:02:01 AM
#1144   Well, something they own 1/3 of announced positive pymadams 01/30/19 03:10:21 AM
#1143   so this is riding on the back of madras50 01/29/19 08:53:45 PM
#1142   * * $BTX Video Chart 01-29-2019 * * ClayTrader 01/29/19 05:49:32 PM
#1141   see POST #1135 for whats moving the ahab333 01/29/19 01:18:17 PM
#1140   Nvm, I found this article: https://www.streetinsider.com/Corporate+News/BioTime+ HonTer 01/29/19 01:08:41 PM
#1139   Thanks for that info. I hadn't seen it tradetrak 01/29/19 01:06:51 PM
#1138   Why is that? Is that because BTX owns HonTer 01/29/19 12:49:17 PM
PostSubject